{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T14:49:04Z","timestamp":1745074144921},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.mcna.2024.03.003","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T17:54:11Z","timestamp":1712944451000},"page":"953-964","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel Therapies for the Treatment of Cardiovascular Disease"],"prefix":"10.1016","volume":"108","author":[{"given":"Abdul Aziz A.","family":"Asbeutah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary D.","family":"Goldberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2024.03.003_bib1","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart Disease and Stroke Statistics-2023\u00a0Update: A Report From the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2024.03.003_bib2","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.mcna.2024.03.003_bib3","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.mcna.2024.03.003_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ejhf.16","article-title":"Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years","volume":"16","author":"Merlo","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.mcna.2024.03.003_bib5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCOUTCOMES.110.957571","article-title":"Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004)","volume":"3","author":"Stewart","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.mcna.2024.03.003_bib6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2024.03.003_bib7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2024.03.003_bib8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2024.03.003_bib9","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.120.053291","article-title":"The Affordability of Guideline-Directed Medical Therapy: Cost Sharing is a Critical Barrier to Therapy Adoption","volume":"143","author":"Sandhu","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2024.03.003_bib10","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2024.03.003_bib11","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2024.03.003_bib12","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2024.03.003_bib13","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2024.03.003_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13300-014-0089-4","article-title":"Sodium-glucose co-transporter-2 (SGLT2) inhibitors: A review of their basic and Clinical Pharmacology","volume":"5","author":"Kalra","year":"2014","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.mcna.2024.03.003_bib15","first-page":"632","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC (J Am Coll Cardiol): Basic to Translational Science"},{"key":"10.1016\/j.mcna.2024.03.003_bib16","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","article-title":"Initial decline (DIP) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: Insights from DAPA-HF","volume":"146","author":"Adamson","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2024.03.003_bib17","doi-asserted-by":"crossref","first-page":"e921536","DOI":"10.12659\/AJCR.921536","article-title":"Fournier's Gangrene and Diabetic Ketoacidosis Associated with Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Life-Threatening Complications","volume":"21","author":"Kasbawala","year":"2020","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.mcna.2024.03.003_bib18","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/ALN.0000000000003237","article-title":"Perioperative management of oral glucose-lowering drugs in the patient with type 2 diabetes","volume":"133","author":"Preiser","year":"2020","journal-title":"Anesthesiology"},{"key":"10.1016\/j.mcna.2024.03.003_bib19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41540-017-0013-4","article-title":"Mechanisms of action of sacubitril\/valsartan on cardiac remodeling: a systems biology approach","volume":"3","author":"Iborra-Egea","year":"2017","journal-title":"NPJ Syst Biol Appl"},{"key":"10.1016\/j.mcna.2024.03.003_bib20","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2024.03.003_bib21","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2024.03.003_bib22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/FJC.0000000000000643","article-title":"Titration and Tolerability of Sacubitril\/Valsartan for Patients With Heart Failure in Clinical Practice","volume":"73","author":"Du","year":"2019","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.mcna.2024.03.003_bib23","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jacc.2019.01.018","article-title":"B-Type Natriuretic Peptide During Treatment With Sacubitril\/Valsartan: The PARADIGM-HF Trial","volume":"73","author":"Myhre","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.mcna.2024.03.003_bib24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2022.10.033","article-title":"Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors","volume":"81","author":"Eworuke","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.mcna.2024.03.003_bib25","first-page":"810","article-title":"Ivabradine (Corlanor) for Heart Failure: The First Selective and Specific I f Inhibitor","volume":"40","author":"Tse","year":"2015","journal-title":"PT"},{"key":"10.1016\/j.mcna.2024.03.003_bib26","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2024.03.003_bib27","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2024.03.003_bib28","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/pace.12118","article-title":"Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients","volume":"36","author":"Benezet-Mazuecos","year":"2013","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.mcna.2024.03.003_bib29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jchf.2022.06.005","article-title":"Angiotensinogen: more than its downstream products: evidence from population studies and novel therapeutics","volume":"10","author":"Kahlon","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.mcna.2024.03.003_bib30","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.117.09755","article-title":"Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury","volume":"70","author":"Mullick","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.mcna.2024.03.003_bib31","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/HYPERTENSIONAHA.119.12703","article-title":"Strong and sustained antihypertensive effect of small interfering RNA targeting liver angiotensinogen","volume":"73","author":"Uijl","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.mcna.2024.03.003_bib32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2024.03.003_bib33","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1139\/cjpp-2022-0010","article-title":"Aprocitentan and the endothelin system in resistant hypertension","volume":"100","author":"Clozel","year":"2022","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.mcna.2024.03.003_bib34","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1161\/HYPERTENSIONAHA.108.117366","article-title":"Role of endothelin-1 in clinical hypertension: 20 years on","volume":"52","author":"Dhaun","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.mcna.2024.03.003_bib35","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(09)61500-2","article-title":"A\u00a0selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Weber","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2024.03.003_bib36","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0895-7061(02)02933-3","article-title":"HEAT Investigators. Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension","volume":"15","author":"Nakov","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.mcna.2024.03.003_bib37","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","article-title":"The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators","volume":"338","author":"Krum","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2024.03.003_bib38","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2024.03.003_bib39","doi-asserted-by":"crossref","first-page":"765876","DOI":"10.3389\/fcvm.2021.765876","article-title":"Stable Rates of Obstructive Hypertrophic Cardiomyopathy in a Contemporary Era","volume":"8","author":"Butzner","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.mcna.2024.03.003_bib40","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2147\/DDDT.S368590","article-title":"Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions","volume":"17","author":"Dong","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.mcna.2024.03.003_bib41","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A\u00a0small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.mcna.2024.03.003_bib42","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2024.03.003_bib43","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2024.03.003_bib44","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.mcna.2024.03.003_bib45","doi-asserted-by":"crossref","first-page":"e006853","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","article-title":"Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy","volume":"13","author":"Ho","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.mcna.2024.03.003_bib46","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712524000208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712524000208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T06:11:07Z","timestamp":1722319867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712524000208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0025712524000208"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2024.03.003","relation":{},"ISSN":["0025-7125"],"issn-type":[{"type":"print","value":"0025-7125"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Therapies for the Treatment of Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2024.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}